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There is controversy about the status of schizoaffective 
disorder depressive-type (SA-D), particularly whether 
it should be considered a form of schizophrenia or a dis-
tinct disorder. We aimed to determine whether individuals 
with SA-D differ from individuals with schizophrenia in 
terms of demographic, premorbid, and lifetime clinical 
characteristics, and genetic liability to schizophrenia, de-
pression, and bipolar disorder. Participants were from the 
CardiffCOGS sample and met ICD-10 criteria for schizo-
phrenia (n = 713) or SA-D (n = 151). Two samples, Cardiff 
Affected-sib (n = 354) and Cardiff F-series (n = 524), were 
used for replication. For all samples, phenotypic data were 
ascertained through structured interview, review of med-
ical records, and an ICD-10 diagnosis made by trained re-
searchers. Univariable and multivariable logistic regression 
models were used to compare individuals with schizophrenia 
and SA-D for demographic and clinical characteristics, and 
polygenic risk scores (PRS). In the CardiffCOGS, SA-D, 
compared to schizophrenia, was associated with female 
sex, childhood abuse, history of alcohol dependence, higher 
functioning Global Assessment Scale (GAS) score in worst 
episode of psychosis, lower functioning GAS score in worst 
episode of depression, and reduced lifetime severity of dis-
organized symptoms. Individuals with SA-D had higher de-
pression PRS compared to those with schizophrenia. PRS 
for schizophrenia and bipolar disorder did not significantly 
differ between SA-D and schizophrenia. Compared to in-
dividuals with schizophrenia, individuals with SA-D had 
higher rates of environmental and genetic risk factors for 
depression and a similar genetic liability to schizophrenia. 
These findings are consistent with SA-D being a sub-type 
of schizophrenia resulting from elevated liability to both 
schizophrenia and depression.
Key words:  polygenic risk score/depression/psychosis/di
agnosis/phenotypes
Introduction
Schizoaffective disorder depressive-type (SA-D) is char-
acterized by the co-occurrence of depressive episodes 
with core features of schizophrenia.1 However, the va-
lidity of schizoaffective disorder, both depressive-type 
and bipolar-type (SA-BP), has long been debated,2 par-
ticularly given evidence of limited inter-rater reliability 
and low stability over time.3,4 Issues with reliability and 
stability may in part be driven by a lack of consensus on 
the definition of SA-D, particularly in terms of the du-
ration and overlap of psychosis and depression. ICD-10 
requires 2 weeks or more of psychosis, with psychosis 
and depression concurrent for at least part of the epi-
sode. DSM-IV5 requires psychosis for at least 1 month, 
including at least 2 weeks of hallucinations or delusions 
in the absence of any prominent symptoms of depres-
sion; depression must also occur for a substantial portion 
of the total illness. The major change in DSM-56 was that 
depression was required to be present for the majority of 
the total duration of the lifespan of the illness (see table 1 
for full criteria). As this criterion requires continuous ob-
servation over time, individuals can fluctuate between 
meeting and not meeting the diagnostic criteria, thus 
leading to an exaggerated perception of schizoaffective 
disorder as an unstable diagnosis.7
Research into schizoaffective disorder has often com-
bined bipolar and depressive subtypes, despite evidence 
supporting their distinction.8 Studies that have done so 
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an intermediate category between schizophrenia and bi-
polar disorder. Individuals with schizoaffective disorder 
are more likely than individuals with schizophrenia to 
have been married, to have better cognitive functioning, 
and to have a better treatment response.9 Compared 
to individuals with mood disorders, individuals with 
schizoaffective disorder had poorer outcomes for these 
characteristics, as well as for various other demographics 
and clinical characteristics.9 Patterns of familial aggrega-
tion have also been reported to differ between those with 
schizophrenia, schizoaffective disorder, and bipolar dis-
order. In comparison with healthy controls, people with 
schizoaffective disorder have a higher family history of 
schizophrenia, schizoaffective disorder, and bipolar dis-
order,10,11 while diagnoses of  schizophrenia or bipolar 
disorder are most strongly associated with a family his-
tory of schizophrenia or bipolar disorder, respectively.11 
However, as noted above, much of this research has com-
bined (or not distinguished between) bipolar and depres-
sive subtypes of  schizoaffective disorder, and therefore it 
is unclear whether these findings are applicable to both 
or only one subtype.
Studies that have distinguished SA-D from SA-BP have 
found that people with SA-D typically have poorer func-
tioning than individuals with a diagnosis of psychotic 
depression, but better functioning than individuals with 
schizophrenia across a range of measures, including 
cognitive, premorbid, and overall functioning.12,13 In 
the context of shared symptoms, SA-D might be better 
considered an intermediate between schizophrenia and 
major depressive disorder14 rather than between schiz-
ophrenia and bipolar disorder. A twin study found that 
co-twins of individuals with SA-D were more likely to 
experience schizophrenia, SA-D, SA-BP, mania, and 
psychotic depression, than co-twins of unaffected con-
trols.8 Therefore, SA-D may arise from elevated liability 
to schizophrenia and depression, and, to a lesser extent, 
mania.15 Family studies have supported this conclusion, 
showing that relatives of individuals with SA-D are at 
higher risk of schizophrenia, depression, and bipolar dis-
order,16 compared to relatives of unaffected individuals. 
Although SA-D, like schizophrenia and bipolar disorder, 
is highly heritable (around 80%),17 there has been very 
little genetic research into SA-D, individuals with SA-D 
being generally treated as if  they have a diagnosis of 
schizophrenia.18
More research is needed to clarify the relationship be-
tween schizophrenia and SA-D in order to improve our 
understanding of  the etiology of  SA-D, and its relation-
ships with other disorders, particularly schizophrenia 




Symptoms from at least one group:  
a)  Thought echo, insertion, with-
drawal, or broadcasting  
b)  Delusions of control, influence, or 
passivity  
c)  Running commentary, third person 
voices, or voices coming from part 
of the body  
d)  Bizarre or impossible delusions  
e)  Grossly irrelevant or incoherent 
speech, or frequent use of neolo-
gisms  
f)  Intermittent but frequent catatonic 
behavior
Two or more of the following:  
a)  Delusions  
b)  Hallucinations  
c) Disorganized speech  
d)  Grossly disorganized or catatonic 
behavior  
e)  Negative symptoms  
-  Only one symptom is required 
if  delusions are bizarre or hal-
lucinations consist of running 
commentary or 2 or more voices 
conversing with each other.
Two or more of the following, at least 
one must be a), b), or c):  
a)  Delusions  
b)  Hallucinations  
c)  Disorganized speech  
d)  Grossly disorganized or catatonic 
behavior  
e)  Negative symptoms
Depression 
criteria
A depressive episode of at least mod-
erate severity.
A major depressive episode that 
must include depressed mood.
A major depressive episode that must 
include depressed mood.
Duration -  Psychosis criteria must be present for 
most of the time during a period of 
at least 2 wk.  
-  Psychosis and depression must be 
met within the same episode, and 
concurrently for at least part of the 
episode.
-  Uninterrupted period during 
which depression is concurrent 
with psychosis.  
-  Psychosis criteria must be present 
for a significant portion of time 
during a 1-mo period.  
-  Delusions or hallucinations for 2 
or more weeks in the absence of 
mood during the lifetime duration 
of the illness.  
-  Depression symptoms are present 
for a substantial portion of the 
total duration of the active and re-
sidual portions of the illness.
-  Uninterrupted period during which 
depression is concurrent with psy-
chosis.  
-  Psychosis criteria must be present 
for a significant portion of time 
during a 1-mo period.  
-  Delusions or hallucinations for 2 or 
more weeks in the absence of mood 
during the lifetime duration of the 
illness.  
-  Depression symptoms are present 
for the majority of the total dura-
tion of the active and residual por-
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and depression. Here, we aimed to establish whether 
individuals with SA-D differ from those with schizo-
phrenia in terms of  demographics, family history, pre-
morbid factors, lifetime clinical characteristics, and 




Participants were drawn from CardiffCOGS,19 a cross-sec-
tional study of individuals with a clinical diagnosis of 
schizophrenia or a related psychotic disorder. Individuals 
were recruited to CardiffCOGS from secondary psychi-
atric services between 2009 and 2017, completed a research 
interview based on the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN).20 Two additional samples 
were used for replication: the Cardiff  Affected-sib and 
Cardiff  F-series samples. Families were recruited from 
mental health services and relatives’ support groups to 
the Cardiff  Affected-sib study21 from 1994–1997 where 
at least 2 affected siblings had a diagnosis of schizo-
phrenia or a schizoaffective disorder. Affected sibling 
pairs where both individuals had a diagnosis of SA-BP 
were excluded. Unrelated individuals with a clinical di-
agnosis of schizophrenia or SA-D were recruited to the 
F-series study22 from 1997–2001, primarily through NHS 
secondary care services and additionally via an advertise-
ment in a volunteer support organization. Participants 
in Cardiff  Affected-sib and Cardiff  F-series completed a 
research interview based on the SCAN or Present State 
Examination23 (PSE-9). Compared to the CardiffCOGS, 
the Cardiff  Affected-sib and Cardiff  F-series samples 
had a smaller number of phenotypic variables, and thus 
replication was restricted to those which were available 
across all 3 datasets. All studies have relevant NHS eth-
ical approvals and all participants provided written in-
formed consent.
For all 3 samples, trained researchers reviewed this 
information and completed lifetime assessments using 
the Operational Checklist Criteria for Psychotic Illness 
and Affective Illness (OPCRIT)24 and the SAPS and 
SANS,25,26 and reached a consensus diagnosis using 
ICD-101 criteria. Individuals with a lifetime research 
diagnosis of  ICD-10 schizophrenia or SA-D were 
included in the present study (table 2). Cohen’s kappa 
for inter-rater reliability for ICD-10 diagnoses within 
the Cardiff  COGS sample was substantial (k = 0.76). 
Cardiff  Affected-sib have previously reported an av-
erage κ score of  0.9 against consensus, indicating ex-
cellent reliability for diagnosis.21 Cardiff  F-series 
previously reported a kappa >0.8 between raters for 
diagnosis.
Full definitions of all demographics, premorbid, and 
lifetime clinical characteristics are provided in supple-
mentary table 1.
Demographics, Family History, and Premorbid 
Characteristics
Details of demographics, family history, and premorbid 
characteristics were taken from the research interview, 
clinical case notes, and OPCRIT items. We obtained in-
formation on the following demographics: sex, family 
history of psychiatric illness, marital status, number 
of children, maximum educational attainment, and 
urbanicity, as well as on the following premorbid fac-
tors: premorbid social functioning, obstetric complica-
tions, premorbid IQ, and history of childhood physical 
or sexual abuse.27
Lifetime Clinical Characteristics and Outcomes
Lifetime clinical characteristics were also derived from 
interview, clinical case notes, and OPCRIT items, 
and included course of  disorder, mode of  onset, an-
tipsychotic response, MATRICS28 composite cogni-
tion, alcohol dependence, cannabis dependence, and 
other substance dependence. The following were in-
cluded with respect to psychosis: age at onset of  im-
pairment, number of  admissions, ever detained under 
the UK Mental Health Act 1983 for psychotic symp-
toms, number of  episodes, and Global Assessment 
Scale (GAS) score regarding lowest level of  functioning 
in worst episode. Measures of  symptom severity were 
derived by combining the raw global scores from the 
lifetime most severe SAPS and SANS25,26 ratings (Legge 
et al., in submission). A positive symptoms score was 
calculated from the global hallucinations and global 
delusions scores; a disorganized symptoms score was 
calculated from global positive formal thought dis-
order and the inappropriate affect item; a diminished 
expressivity score was calculated from global affective 
flattening and global alogia; a reduced motivation and 
pleasure score was calculated from the global scores for 
avolition/apathy and anhedonia/asociality.
For individuals who had experienced at least one de-
pressive episode under ICD-10 criteria, we included the 
following characteristics specific to the depressive epi-
sode: age at first impairment, age at first admission, ever 
admitted to hospital, longest episode duration, number 
Table 2. Number of Participants Included From Each Study 
With an ICD-10 Diagnosis of Schizophrenia and SA-D
Study Schizophrenia SA-D Total
CardiffCOGS 713 151 864
Affected-sib 330 24 354
F-series 505 19 524
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of episodes, GAS score in worst episode, and whether de-
pression onset occurred prior to psychosis onset.
Genetic Data
The CardiffCOGS sample were genotyped in 2 waves on 
the Illumina HumanOmniExpressExome-8 and on the 
Illumina HumanOmniExpress-12. SNPs were excluded 
if: minor allele frequency (MAF) <0.01, genotyping rate 
<0.95, or Hardy-Weinberg equilibrium (HWE) P-value < 
1  × 10−6. Samples missing >5% of genotypes were also 
excluded. Genotypes were imputed using the Haplotype 
Reference Consortium29 v1.1 reference panel. Best esti-
mate genotype data were filtered to exclude by imputation 
quality score <0.8 and HWE P < value <1 × 10−4. PLINK 
v2.030 was used to derive principal components for an-
cestry using SNPs with low levels of linkage disequilib-
rium, defined as r2 < 0.2, within 500kb windows. Principal 
components were used to restrict genetic analyses to in-
dividuals of European ancestry. Pairs of individuals with 
a kinship score >0.125 were identified and one member 
of each pair removed, preferentially retaining those with 
more complete phenotype data. Post-QC, genetic data 
were available for 692 individuals. Ten individuals were 
excluded due to ancestry restrictions, and 12 due to relat-
edness leaving 561 individuals with schizophrenia and 109 
individuals with SA-D in the genetic liability analysis.
Genetic analyses within the Cardiff  Affected-sib and 
Cardiff  F-series samples is impaired due to the small 
number of individuals with SA-D, limited availability of 
high quality genetic data, and relatedness amongst the 
participants. Thus, polygenic analyses were restricted to 
the CardiffCOGS sample only.
Polygenic Risk Scores
Polygenic risk scores (PRS) were derived using PRSice31 
based on SNPs with INFO >0.9, MAF >0.10, and in rel-
ative linkage equilibrium (i2 <0.2 within 500kb windows), 
following criteria used by the Psychiatric Genomics 
Consortium.18 The extended major histocompatibility 
complex region (25–34Mb) was excluded due to its com-
plex LD structure. PRS were calculated using the largest 
available genome-wide association summary statistics for 
schizophrenia,32 depression,33 and bipolar disorder34 at 6 
thresholds: 5 × 10−8, 1 × 10−4, 0.001, 0.05, 0.1, and 0.5. 
Summary statistics used to define the association thresh-
olds were generated after exclusion of the CardiffCOGS 
from the GWAS study. PRS were standardized as 
Z-scores. A  pre-specified primary threshold of P < .05 
for risk alleles for each disorder PRS was chosen given 
evidence that it is the optimal threshold for capturing 
schizophrenia liability.18 The other thresholds were also 
analyzed to ensure the results were not highly sensitive to 
our primary test threshold.
Analysis
Univariable Analysis
Primary analyses were conducted within the CardiffCOGS 
sample. The continuous variables were standardized as 
Z-scores to allow for comparison across characteristics. 
Primary analyses involved testing for differences between 
schizophrenia and SA-D via logistic regression with re-
spect to individual demographics and clinical character-
istics. As we found a significant association between sex 
and diagnosis, all other analyses were covaried for sex, as 
well as age at interview. Depression characteristics were 
analyzed only in those with at least one depressive epi-
sode (N = 426 with schizophrenia, n = 151 with SA-D).
Replication
The demographic and clinical characteristics that were 
significantly associated in the primary univariable anal-
ysis (P < .05) and that were available in both the Cardiff  
Affected-sib and Cardiff  F-series samples were tested for 
replication (see supplementary table 2 for characteristics 
included). A meta-analysis was conducted of the results 
from the Cardiff  Affected-sib and Cardiff  F-series sam-
ples, using a fixed effect model weighted by standard 
error, conducted in the R package meta.35
Multivariable Analysis
For variables that were associated with SA-D (P < 0.05) 
in the univariable analyses, we performed multivariable 
analysis to clarify whether the associations were inde-
pendent. Characteristics were grouped into 4 categories 
which were analyzed separately: demographics and pre-
morbid; psychosis; depression; other clinical, (see supple-
mentary table  7 for groupings of characteristics). Each 
regression model contained sex and age at interview as 
covariates, with diagnosis as the outcome.
Polygenic Risk Scores
Polygenic risk scores (PRS) were analyzed using logistic 
regressions, with principal components 1 to 5 and sex in-
cluded as covariates.
Results
Demographics, Family History, and Premorbid 
Characteristics
In the univariable analyses, compared to schizophrenia, 
SA-D was associated with female sex (OR = 3.19, 95% 
confidence intervals [CI]  =  2.23–4.59, P  =  2.8  × 10−10), 
self-reported experience of childhood abuse (OR = 2.07, 
CI = 1.35–3.17, P =7.9 × 10−4), obstetric complications 
(OR  =  1.62, CI  =  1.03–2.50, P  =  .03), and family his-
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(OR  =  1.50, CI  =  1.01–2.22, P  =  .04) but not family 
history of schizophrenia. Those with SA-D had a 
greater number of children (OR = 1.34, CI = 1.08–1.67, 
P = 0.01), and higher premorbid IQ (OR = 1.28, 95%CI= 
1.04–1.60, P = 0.02) than individuals with schizophrenia 
(figure 1 and supplementary table 3).
Lifetime Clinical Characteristics
Compared to schizophrenia, SA-D was associated with 
alcohol dependence (OR = 2.12, CI=1.41–3.20, P = 3.2 × 
10−4), positive antipsychotic response (OR  =  1.59, 
CI = 1.08–2.35, P =  .02), better current cognitive func-
tioning (OR = 1.20, CI = 1.04–1.40, P = .01), and a less 
chronic course of disorder (OR = 0.81, CI = 0.67–0.97, 
P = .02). SA-D was also associated with milder psychosis 
related phenotypes, namely better functioning GAS score 
in worst episode of psychosis (OR  =  1.44, CI  =  1.20–
1.72, P  =  5.8  × 10−5), older age at onset of psychosis 
(OR = 1.26, CI = 1.03–1.54, P =  .02), reduced severity 
of disorganized symptoms (OR = 0.81, CI = 0.72–0.91, 
P  =  5.3  × 10−4), and a lower risk for being detained 
under the mental health act for psychosis (OR  =  0.40, 
CI = 0.22–0.75, P = 3.2 × 10−3) (figure 1 and supplemen-
tary table 3).
To investigate differences in depression symptoms and 
outcomes between those with SA-D and schizophrenia, 
we restricted the schizophrenia sample to those who 
had experienced at least one episode of ICD-10 defined 
Fig. 1. Odds ratios (OR) and confidence interval for each characteristic in the Cardiff  COGS sample. OR > 1 indicates association with 
SA-D; OR < 1 indicates association with schizophrenia. Clinical characteristics of depression are analyzed only in participants with at 
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depression. SA-D was strongly associated with the 
onset of  depression occurring prior to psychosis onset 
(OR=2.88, CI=1.59–5.47, P = 7.1 × 10−4) and a greater 
likelihood of an admission for depression (OR=2.24, 
CI=1.48–3.40, P  =  1.4  × 10−4). SA-D was also associ-
ated with longer duration of depression (OR  =  1.46, 
CI  =  1.19–1.84, P  =  6.0  × 10−4), more episodes of  de-
pression (OR  =  1.43, CI  =  1.18–1.75, P  =  3.7  × 10−4), 
and lower functioning GAS score in worst episode of de-
pression (OR  =  0.47, CI  =  0.37–0.59, P  =  2.0  × 10−10) 
(figure 1 and supplementary table 3).
Full results are presented in supplementary table 3. As 
sex was the strongest predictor of diagnosis, we looked 
for sex-specific effects across all lifetime demographic 
and clinical characteristics but the results were consistent 
between females and males (supplementary figure  1). 
Univariable analyses were repeated using DSM-IV de-
fined schizophrenia and SA-D, and effect sizes were 
consistent between ICD-10 and DSM-IV for all char-
acteristics (supplementary table  4). Additionally, we 
tested for differences between individuals with SA-D and 
SA-BP. We note the since the SA-BD sample is very small 
(N = 104 individuals with ICD-10 SA-BP), and follow up 
samples were not available, we consider the results as pro-
visional (supplementary table 5).
Replication
Five of  the variables associated with SA-D in 
CardiffCOGS were present in the Cardiff  Affected-sib 
and Cardiff  F-series samples. In the replication samples 
all 5 of  these variables were associated with SA-D with 
the same direction of  effect as the original associations, 
with 3 of  these reaching significance. SA-D was signifi-
cantly associated with female sex (OR = 2.32, CI = 1.21–
4.44, P = .01), family history of  psychiatric disorder 
other than schizophrenia (OR  =  2.83, CI  =  1.31–6.13, 
P = .01), and older age at onset of  psychosis (OR = 1.73, 
CI = 1.26–2.37, P = 7.4 × 10−4) (supplementary table 6 
and figure 2). When all 3 samples were meta-analyzed, 
SA-D was significantly associated with all 5 characteris-
tics (figure 2).
Multivariable Models
In the demographics and premorbid model, SA-D 
remained significantly associated with female sex 
(OR  =  2.22, CI  =  1.14–4.36, P  =  .02), and experi-
ence of  childhood abuse (OR  =  2.80, CI  =  1.36–5.71, 
P = 4.6 × 10−3), but not with family history of  psychi-
atric illness, number of  children, obstetric complica-
tions, premorbid IQ, or age at onset of  psychosis. In the 
Fig. 2. Odds ratios (OR) and confidence interval for each lifetime clinical characteristic included in the replication and meta-analysis, 
analyzed in the CardiffCOGS sample, the replication samples, or in the meta-analysis of all samples. OR > 1 indicates association with 
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clinical characteristics model, greater alcohol depend-
ence was significantly associated with SA-D (OR = 2.08, 
CI = 1.31–3.28, P = 1.8 × 10−3), but not with course of 
disorder, cognition, or antipsychotic response. In the 
psychosis model, SA-D was significantly associated with 
better functioning GAS score in worst episode of  psy-
chosis (OR = 1.31, CI = 1.07–1.61, P = .01) and reduced 
lifetime severity of  disorganized symptoms (OR = 0.84, 
CI = 0.74–0.96, P =  .01), but not with being detained 
under the mental health act for psychosis. In the depres-
sion model, SA-D was associated with a greater number 
of  episodes of  depression (OR = 1.62, CI = 1.14–2.32, 
P  =  .01), and lower functioning GAS score in worst 
episode of  depression (OR  =  0.49, CI  =  0.33–0.72, 
P  =  4.8  × 10−4), but not with ever being admitted for 
depression, longest duration of  depression, or having 
depression onset prior to psychosis onset. Full results 
for the multivariable models are presented in supple-
mentary table 7.
In order to better compare the univariable and 
multivariable models, we repeated the significant 
univariable analyses restricted to individuals who had 
complete data for the variables entered into the appro-
priate multivariable model. Effect sizes remained con-
sistent between the restricted and full sample analyses 
and are presented in supplementary table 7.
Polygenic Risk Scores
At the primary p-value threshold of p<0.05, schizo-
phrenia PRS was not significantly different between in-
dividuals with SA-D and with schizophrenia (OR = 0.94, 
CI = 0.77–1.17, P = .60). Bipolar disorder PRS was also 
not significantly different between individuals with SA-D 
and with schizophrenia (OR  =  1.13, CI  =  0.91–1.42), 
P = .27). Depression PRS was significantly higher in in-
dividuals with SA-D compared to individuals with schiz-
ophrenia (OR = 1.26, CI = 1.02–1.56, P = .03) (figure 3). 
These results were broadly consistent across P -value 
thresholds (supplementary table 8).
Discussion
We present novel evidence to show that SA-D differs from 
schizophrenia in terms of demographics, clinical course, 
outcomes, and genetic liability to depression, but not ge-
netic liability to schizophrenia.
Greater Environmental and Genetic Risk for Depression 
in SA-D
Several risk factors for depression occurred more fre-
quently in people with SA-D, compared with those 
with schizophrenia, including female sex, experience 
Fig. 3. Odds ratios (OR) and 95% confidence intervals for all thresholds tested for schizophrenia, depression and bipolar disorder 
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of  childhood physical and/or sexual abuse, and alcohol 
dependence.36–38 Previous twin research has suggested 
that individuals with SA-D may have an elevated ge-
netic liability to depression8; we support this with 
novel evidence that PRS for depression is elevated in 
individuals with SA-D compared to those with schiz-
ophrenia, who themselves are known to have elevated 
genetic liability to depression compared with con-
trols.39 Family history of  psychiatric disorders, other 
than schizophrenia, was also associated with SA-D in 
the univariable analysis and replicated in additional 
samples, further suggesting that individuals with SA-D 
may have an elevated genetic liability to other dis-
orders. Individuals with schizophrenia and SA-D did 
not significantly differ in terms of  genetic liability to 
schizophrenia or environmental risk factors for schiz-
ophrenia, including urbanicity, poor premorbid social 
functioning, and cannabis dependence.40 Thus, SA-D 
may represent a subset of  people with schizophrenia 
but who have an additional burden of  environmental 
and genetic risk factors for depression.
Greater Severity of Depression
Prominence of  depressive episodes in the clinical pic-
ture is a criterion for SA-D, suggesting that individuals 
with SA-D should experience more severe depression 
than individuals with schizophrenia. Our univariable 
analyses support this, while the multivariable analysis 
of  depression characteristics found that the number of 
episodes of  depression and the functioning in the worst 
episode of  depression were the variables most strongly 
associated with SA-D. As our analysis of  depression 
characteristics was restricted to individuals who had ex-
perienced at least one episode of  depression, the asso-
ciations with depression characteristics are not due to 
the presence of  individuals with schizophrenia without 
comorbid depression.
Reduced Burden of Psychosis
Individuals with SA-D had better psychosis related out-
comes, predominantly characterized in the multivariable 
analysis by better functioning in the worst episode of 
psychosis and reduced lifetime severity of disorganized 
symptoms. These findings are consistent with a number 
of studies showing reduced severity of psychotic symp-
toms in schizoaffective disorders compared to schizo-
phrenia,9,41 although those studies did not stratify by 
subtype of schizoaffective disorder. Despite the clinical 
characteristics suggesting a less severe psychosis pheno-
type in those with SA-D, schizophrenia polygenic risk 
score did not significantly differentiate between SA-D 
and schizophrenia. Previous research has found that 
schizophrenia PRS is not significantly associated with 
psychosis related variables, such as positive symptom 
severity42 (Legge et  al., in submission), in people with 
schizophrenia. In this respect, schizophrenia PRS does 
not seem to relate to psychosis severity measures or out-
comes in those with schizophrenia or SA-D.
Neurodevelopmental Spectrum
It has been postulated that schizophrenia lies on a spec-
trum of neurodevelopmental disorders, with intellectual 
disability and autism spectrum disorders having a greater 
neurodevelopmental component than schizophrenia, 
and affective disorders having less.43 The results of our 
univariable analysis, particularly with regard to female 
sex, better current cognitive functioning, less chronic 
course of disorder, older age at onset of psychosis, and 
greater burden of affective symptoms, suggests that 
SA-D may occupy a less severe position on this pro-
posed spectrum than schizophrenia.44 Whilst not all of 
these neurodevelopmental risk factors were associated 
in the multivariable models, we note that the effect sizes 
of these variables are comparable to those found in the 
univariable models.
Previous research that did not distinguish between 
SA-BP and SA-D has shown mixed findings when com-
paring schizoaffective disorders to schizophrenia. Some 
studies reported a higher proportion of women with 
schizoaffective disorder compared to schizophrenia,9,45 
which we found to be one of the most substantial differ-
ences between individuals with SA-D and schizophrenia. 
At a population level, women are more likely to experi-
ence depression than men,36 and it is possible that this 
may also be the case for depression comorbid with other 
primary psychiatric diagnoses.
Limitations
Our study is limited by the relatively small number of indi-
viduals with SA-D, and although we have replicated some 
of the key findings, validation in other samples is nec-
essary to examine whether our findings are fully robust 
to, for example, unknown biases in ascertainment. Whilst 
we did not detect any between group differences in schiz-
ophrenia or bipolar disorder PRS, given our relatively 
small target sample there could be differences between 
the group that we are not powered to detect. The propor-
tion of individuals with SA-D differed across the samples, 
with the Cardiff  Affected-sib and Cardiff  F-series sam-
ples containing fewer individuals with SA-D compared 
to schizophrenia than was seen in the CardiffCOGS. This 
is likely to be because depression data for participants in 
the CardiffCOGS was derived from both clinical records 
and from direct questions about depressive symptoms 
and episodes as part of the SCAN interview, whereas 
participants in Cardiff  Affected-sib and Cardiff  F-series 
were not directly asked these questions, but this data was 
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Conclusions
Compared to schizophrenia, SA-D was associated 
with several risk factors for depression, including fe-
male sex and greater alcohol dependence. We observed 
an increased burden of  depression in individuals with 
SA-D, including higher polygenic risk score for depres-
sion, compared to individuals with schizophrenia. Our 
results are consistent with SA-D being a form of  schiz-
ophrenia which is modified by an elevated liability to 
depression.
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